Longqin Hu - Publications

Affiliations: 
Chemistry, Pharmaceutical Rutgers University, New Brunswick, New Brunswick, NJ, United States 
Area:
Pharmaceutical Chemistry

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Basu S, Yang J, Xu B, Magiera-Mularz K, Skalniak L, Musielak B, Kholodovych V, Holak TTA, Hu L. Design, synthesis, evaluation and structural studies of C2-symmetric small molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) protein-protein interaction. Journal of Medicinal Chemistry. PMID 31298541 DOI: 10.1021/acs.jmedchem.9b00795  1
2018 Yang J, Hu L. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. Medicinal Research Reviews. PMID 30215856 DOI: 10.1002/med.21530  1
2018 Yang Y, Albanyan H, Lee S, Aloysius H, Liang JJ, Kholodovych V, Sahota A, Hu L. Design, synthesis, and evaluation of l-cystine diamides as l-cystine crystallization inhibitors for cystinuria. Bioorganic & Medicinal Chemistry Letters. PMID 29571572 DOI: 10.1016/j.bmcl.2018.03.024  1
2017 Shen J, Magesh S, Chen L, Hu L, He Y. Enantiomeric characterization and structure elucidation of LH601A using vibrational circular dichroism spectroscopy. Spectrochimica Acta. Part a, Molecular and Biomolecular Spectroscopy. 192: 312-317. PMID 29172127 DOI: 10.1016/j.saa.2017.11.033  0.68
2016 Hu L, Yang Y, Aloysius H, Albanyan H, Yang M, Liang JJ, Yu AC, Shtukenberg AG, Poloni LN, Kholodovych V, Tischfield JA, Goldfarb DS, Ward MD, Sahota A. L-CYSTINE DIAMIDES AS L-CYSTINE CRYSTALLIZATION INHIBITORS FOR CYSTINURIA. Journal of Medicinal Chemistry. PMID 27409142 DOI: 10.1021/acs.jmedchem.6b00647  1
2016 Toh MF, Suh W, Wang H, Zhou P, Hu L, You G. Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4. International Journal of Biochemistry and Molecular Biology. 7: 11-8. PMID 27335682  1
2016 Wu X, Hu L. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen. Bioorganic & Medicinal Chemistry. PMID 27156193 DOI: 10.1016/j.bmc.2016.04.035  1
2015 Abed DA, Goldstein M, Albanyan H, Jin H, Hu L. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharmaceutica Sinica. B. 5: 285-299. PMID 26579458 DOI: 10.1016/j.apsb.2015.05.008  1
2015 Aloysius H, Hu L. Improving the Specificity of the Prostate-Specific Antigen Substrate Glutaryl-Hyp-Ala-Ser-Chg-Gln as a Promoiety. Chemical Biology & Drug Design. PMID 25777622 DOI: 10.1111/cbdd.12559  0.48
2015 Sullivan JA, Tong JL, Wong M, Kumar A, Sarkar H, Ali S, Hussein I, Zaman I, Meredith EL, Helsby NA, Hu L, Wilkinson SR. Unravelling the role of SNM1 in the DNA repair system of Trypanosoma brucei. Molecular Microbiology. 96: 827-38. PMID 25689597 DOI: 10.1111/mmi.12973  1
2015 Aloysius H, Hu L. Targeted prodrug approaches for hormone refractory prostate cancer. Medicinal Research Reviews. 35: 554-85. PMID 25529338 DOI: 10.1002/med.21333  0.48
2014 Chen L, Magesh S, Wang H, Yang CS, Kong AN, Hu L. Design and synthesis of novel iminothiazinylbutadienols and divinylpyrimidinethiones as ARE inducers. Bioorganic & Medicinal Chemistry Letters. 24: 940-3. PMID 24398297 DOI: 10.1016/j.bmcl.2013.12.072  0.68
2014 Lee JH, Lee KR, Su ZY, Boyanapalli SS, Barman DN, Huang MT, Chen L, Magesh S, Hu L, Kong AN. In vitro and in vivo anti-inflammatory effects of a novel 4,6-bis ((E)-4-hydroxy-3-methoxystyryl)-1-phenethylpyrimidine-2(1H)-thione. Chemical Research in Toxicology. 27: 34-41. PMID 24304388 DOI: 10.1021/tx400315u  1
2013 Jiang Y, Hu L. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA). Bioorganic & Medicinal Chemistry. 21: 7507-14. PMID 24139844 DOI: 10.1016/j.bmc.2013.09.039  1
2013 Voak AA, Gobalakrishnapillai V, Seifert K, Balczo E, Hu L, Hall BS, Wilkinson SR. An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs. The Journal of Biological Chemistry. 288: 28466-76. PMID 23946481 DOI: 10.1074/jbc.M113.494781  1
2013 Hu L, Magesh S, Chen L, Wang L, Lewis TA, Chen Y, Khodier C, Inoyama D, Beamer LJ, Emge TJ, Shen J, Kerrigan JE, Kong AN, Dandapani S, Palmer M, et al. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorganic & Medicinal Chemistry Letters. 23: 3039-43. PMID 23562243 DOI: 10.1016/j.bmcl.2013.03.013  1
2012 Yang Y, Voak A, Wilkinson SR, Hu L. Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation. Bioorganic & Medicinal Chemistry Letters. 22: 6583-6. PMID 23031595 DOI: 10.1016/j.bmcl.2012.09.005  1
2012 Duan P, Li S, Ai N, Hu L, Welsh WJ, You G. Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization. Molecular Pharmaceutics. 9: 3340-6. PMID 22973893 DOI: 10.1021/mp300365t  1
2012 Hu L, Wang B. In honor of Professor Lester A. Mitscher on the occasion of his 80(th) birthday. Medicinal Research Reviews. 32: 685-6. PMID 22777713 DOI: 10.1002/med.21261  0.36
2012 Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Medicinal Research Reviews. 32: 687-726. PMID 22549716 DOI: 10.1002/med.21257  0.68
2012 Inoyama D, Chen Y, Huang X, Beamer LJ, Kong AN, Hu L. Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction. Journal of Biomolecular Screening. 17: 435-47. PMID 22156223 DOI: 10.1177/1087057111430124  0.48
2011 Chen Y, Inoyama D, Kong AN, Beamer LJ, Hu L. Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance. Chemical Biology & Drug Design. 78: 1014-21. PMID 21920027 DOI: 10.1111/j.1747-0285.2011.01240.x  0.48
2011 Wu X, Chen Y, Aloysius H, Hu L. A novel high-yield synthesis of aminoacyl p-nitroanilines and aminoacyl 7-amino-4-methylcoumarins: Important synthons for the synthesis of chromogenic/fluorogenic protease substrates. Beilstein Journal of Organic Chemistry. 7: 1030-5. PMID 21915204 DOI: 10.3762/bjoc.7.117  1
2011 Hu L, Wu X, Han J, Chen L, Vass SO, Browne P, Hall BS, Bot C, Gobalakrishnapillai V, Searle PF, Knox RJ, Wilkinson SR. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs. Bioorganic & Medicinal Chemistry Letters. 21: 3986-91. PMID 21620697 DOI: 10.1016/j.bmcl.2011.05.009  1
2010 Zhao Y, Lee MJ, Cheung C, Ju JH, Chen YK, Liu B, Hu LQ, Yang CS. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. Journal of Agricultural and Food Chemistry. 58: 4844-52. PMID 20222730 DOI: 10.1021/jf904464u  0.36
2010 Hall BS, Wu X, Hu L, Wilkinson SR. Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrobial Agents and Chemotherapy. 54: 1193-9. PMID 20028822 DOI: 10.1128/AAC.01213-09  1
2010 Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L, Hyde EI, Searle PF. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochemical Pharmacology. 79: 102-11. PMID 19665450 DOI: 10.1016/j.bcp.2009.07.025  0.52
2009 Jiang Y, Dipaola RS, Hu L. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA). Bioorganic & Medicinal Chemistry Letters. 19: 2587-90. PMID 19345094 DOI: 10.1016/j.bmcl.2009.03.009  1
2009 Prawan A, Saw CL, Khor TO, Keum YS, Yu S, Hu L, Kong AN. Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling. Chemico-Biological Interactions. 179: 202-11. PMID 19159619 DOI: 10.1016/j.cbi.2008.12.014  0.32
2009 Ge Y, Wu X, Zhang D, Hu L. 3-Aminoxypropionate-based linker system for cyclization activation in prodrug design. Bioorganic & Medicinal Chemistry Letters. 19: 941-4. PMID 19097896 DOI: 10.1016/j.bmcl.2008.11.097  1
2009 Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Medicinal Research Reviews. 29: 29-64. PMID 18688784 DOI: 10.1002/med.20137  0.48
2008 Jiang Y, Hu L. N-(2,2-Dimethyl-2-(2-nitrophenyl)acetyl)-4-aminocyclophosphamide as a potential bioreductively activated prodrug of phosphoramide mustard. Bioorganic & Medicinal Chemistry Letters. 18: 4059-63. PMID 18556201 DOI: 10.1016/j.bmcl.2008.05.099  1
2008 Keum YS, Chang PP, Kwon KH, Yuan X, Li W, Hu L, Kong AN. 3-Morpholinopropyl isothiocyanate is a novel synthetic isothiocyanate that strongly induces the antioxidant response element-dependent Nrf2-mediated detoxifying/antioxidant enzymes in vitro and in vivo. Carcinogenesis. 29: 594-9. PMID 17916901 DOI: 10.1093/carcin/bgm208  0.32
2008 Prawan A, Keum YS, Khor TO, Yu S, Nair S, Li W, Hu L, Kong AN. Structural influence of isothiocyanates on the antioxidant response element (ARE)-mediated heme oxygenase-1 (HO-1) expression. Pharmaceutical Research. 25: 836-44. PMID 17657593 DOI: 10.1007/s11095-007-9370-9  0.32
2007 Wu X, Hu L. Efficient amidation from carboxylic acids and azides via selenocarboxylates: application to the coupling of amino acids and peptides with azides. The Journal of Organic Chemistry. 72: 765-74. PMID 17253793 DOI: 10.1021/jo061703n  1
2007 Jiang Y, Hu L. Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: synthesis, stability, and stereochemical requirements for enzymatic cleavage. Bioorganic & Medicinal Chemistry Letters. 17: 517-21. PMID 17064897 DOI: 10.1016/j.bmcl.2006.10.017  1
2006 Jiang Y, Han J, Yu C, Vass SO, Searle PF, Browne P, Knox RJ, Hu L. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. Journal of Medicinal Chemistry. 49: 4333-43. PMID 16821793 DOI: 10.1021/jm051246n  1
2005 Hu L. Prodrug Approaches to Drug Delivery Drug Delivery: Principles and Applications. 125-165. DOI: 10.1002/0471475734.ch8  1
2004 Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clinical and Experimental Pharmacology & Physiology. 31: 811-6. PMID 15566399 DOI: 10.1111/j.1440-1681.2004.04085.x  0.52
2004 Hu L. Prodrugs: effective solutions for solubility, permeability and targeting challenges. Idrugs : the Investigational Drugs Journal. 7: 736-42. PMID 15334306  1
2004 Hu L. The prodrug approach to better targeting Current Drug Discovery. 28-32.  1
2003 Hu L, Yu C, Jiang Y, Han J, Li Z, Browne P, Race PR, Knox RJ, Searle PF, Hyde EI. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. Journal of Medicinal Chemistry. 46: 4818-21. PMID 14584930 DOI: 10.1021/jm034133h  1
2003 Li Z, Han J, Jiang Y, Browne P, Knox RJ, Hu L. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. Bioorganic & Medicinal Chemistry. 11: 4171-8. PMID 12951148  1
2003 Liu B, Hu L. 5'-(2-Nitrophenylalkanoyl)-2'-deoxy-5-fluorouridines as potential prodrugs of FUDR for reductive activation. Bioorganic & Medicinal Chemistry. 11: 3889-99. PMID 12927849 DOI: 10.1016/S0968-0896(03)00426-7  0.36
2002 Yu C, Hu L. Successful Baylis-Hillman reaction of acrylamide with aromatic aldehydes. The Journal of Organic Chemistry. 67: 219-23. PMID 11777462  0.52
Show low-probability matches.